Construction of Immune-Associated Nomogram for Predicting the Recurrence Survival Risk of Stage I Cervical Cancer

Figure 4

Kaplan-Meier and ROC analysis of patients with stage I CC in the internal validation, external validation, and entire GEO set, respectively. (a, c, e) Kaplan-Meier analysis with a two-sided log-rank test was implemented to test the differences in RFS between the low-risk and high-risk samples. (b, d, f) 1-, 3-, and 5-year ROC curves of the 8-immune gene signature were adopted to examine the power in predicting stage I CC patients’ RFS.

(a)

(b)

(c)

(d)

(e)

(f)